My watch list
my.chemeurope.com  
Login  

21 Current news of Saltigo

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Saltigo increases prices for 1,2,4 Triazol

26-Aug-2010

Saltigo GmbH will be raising its prices for the product group 1,2,4 Triazol (CAS 00288-88-0) by 10 % effective September 1, 2010. The reasons for the measure are substantial increases in raw materials and energy costs.

more

Seal of quality for LANXESS subsidiary: Saltigo passes FDA audit

28-Jun-2010

Saltigo GmbH has passed an audit by the U.S. Food and Drug Administration (FDA) with a “No Findings” rating. Saltigo’s Managing Director Wolfgang Schmitz is delighted that the official auditors did not have any objections: “The FDA audit is an internationally accredited seal of quality and ...

more

Saltigo undertakes major expansion of production

Syngenta invests around EUR 50 million in Saltigo facilities

06-May-2010

Saltigo, a wholly owned subsidiary of LANXESS, is significantly expanding production at its Leverkusen site. This is being made possible by a cooperation agreement that is so far unique for the Group. Syngenta is investing some EUR 50 million in expanding several Saltigo facilities in Leverkusen ...

more

Saltigo successfully defends its title as “Best Supplier”

LANXESS subsidiary wins “Agrow Award 2009”

17-Nov-2009

Saltigo GmbH, a wholly owned subsidiary of LANXESS, has been rated as “Best Supplier” by the “Agrow” trade journal for the second time in succession and won against a strong competition from India, China and Europe. A panel of judges comprising eleven internationally recognized experts from the ...

more

Saltigo targets Japanese custom manufacturing market

02-Jul-2009

Saltigo GmbH targets Japanese custom manufacturing market, presenting its portfolio of services at Interphex/Pharma-i Japan Exhibition in Tokyo. Saltigo’s CEO Wolfgang Schmitz emphasizes: “This is Asia’s largest pharmaceutical industry event and has an excellent reputation for attracting key ...

more

Saltigo: Expansion of capacity for intermediates and active ingredients for agrochemicals

Capacity increase and process optimization possible without interrupting production or limiting supply volumes

05-Jun-2009

Saltigo GmbH has succeeded in more than doubling capacity for five intermediates and two active ingredients for several agrochemical companies without needing to halt or interrupt the production process in any way. For three of these projects, higher volumes were achieved by implementing process ...

more

Saltigo expands without interrupting production

Capacity for active ingredient precursor nearly doubled

02-Feb-2009

Saltigo GmbH has demonstrated its wide-ranging expertise in the fields of synthesis optimization and process development. The global specialist for exclusive custom synthesis has succeeded in increasing capacity for an active ingredient precursor for a major pharmaceutical manufacturer without ...

more

LANXESS: Italian company Endura Fine Chemicals markets active ingredient for insect repellent

13-Mar-2007

LANXESS is extending its activities in the area of insect repellents. LANXESS subsidiary Saltigo and the Italian company Endura SpA Fine Chemicals have signed a contract under whose terms Endura will market Saltigo's active ingredient Bayrepel® (Icaridin) with immediate effect in Central and ...

more

LANXESS plans package of measures to speed development at Saltigo

EUR 30 million investment to modernize the production base / EUR 10 million to build a high-tech multi-purpose plant

18-Jan-2007

LANXESS plans to develop the business of its fine chemicals subsidiary Saltigo. EUR 30 million has been earmarked for plant modernization, and new worktime models are to be introduced. A state-of-the-art multi-purpose facility costing a further EUR 10 million is already under construction. "The ...

more

Ilypsa und Saltigo verkünden Kooperation

09-Jun-2006

Die Saltigo GmbH und die Ilypsa, Inc. gaben die Bildung einer Kooperation zur Prozessentwicklung und Herstellung polymerer Pharmazeutika sowie Bereitstellung von Substanzmengen für die klinische Prüfung bekannt. Diese Geschäftsbeziehung umfasst zunächst Prozessentwicklung und Herstellung von ...

more

Page 2 From 3
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE